| WB | 咨询技术 | Human,Mouse,Rat |
| IF | 咨询技术 | Human,Mouse,Rat |
| IHC | 1/50-1/100 | Human,Mouse,Rat |
| ICC | 1/100-1/200 | Human,Mouse,Rat |
| FCM | 咨询技术 | Human,Mouse,Rat |
| Elisa | 咨询技术 | Human,Mouse,Rat |
| Aliases | Receptor tyrosine-protein kinase ErbB-1; ERBB1; |
| Entrez GeneID | 1956; |
| WB Predicted band size | 175kDa |
| Host/Isotype | Rabbit IgG |
| Antibody Type | Primary antibody |
| Storage | Store at 4°C short term. Aliquot and store at -20°C long term. Avoid freeze/thaw cycles. |
| Species Reactivity | Human |
| Immunogen | Peptide sequence around aa.1068~1072 (R-Y-S-S-D) derived from Human EGFR. |
| Formulation | Purified antibody in PBS with 0.05% sodium azide. |
+ +
以下是3条关于EGFR(Ab-1070)抗体的参考文献示例(注：部分内容为模拟虚构，实际文献需根据具体数据库检索验证)：
1. **"Phosphorylation of EGFR at Tyrosine 1070 Promotes Tumor Invasion in Non-Small Cell Lung Cancer"**
- **作者**: Li, X. et al.
- **摘要**: 研究揭示了EGFR在Y1070位点的磷酸化通过激活下游PI3K/AKT信号通路，增强肺癌细胞迁移和侵袭能力。该文献使用EGFR(Ab-1070)抗体通过免疫印迹验证磷酸化水平，并发现其与患者预后不良相关。
2. **"Structural Basis of EGFR Kinase Domain Activation by Y1070 Autophosphorylation"**
- **作者**: Zhang, Y. & Wang, F.
- **摘要**: 通过X射线晶体学分析，阐明了EGFR Y1070位点自磷酸化对激酶构象变化的调控作用。研究利用EGFR(Ab-1070)抗体进行免疫沉淀，证明该位点磷酸化是受体二聚化和信号传导的关键步骤。
3. **"Targeted Therapy Resistance Mediated by EGFR Y1070 Mutation in Colorectal Cancer"**
- **作者**: Kim, S. et al.
- **摘要**: 报道结直肠癌中EGFR Y1070位点突变导致抗EGFR单抗(如西妥昔单抗)耐药。通过EGFR(Ab-1070)抗体检测磷酸化状态，发现突变体持续激活STAT3通路，提示联合靶向治疗的潜在策略。
如需实际文献，建议在PubMed或Google Scholar中检索关键词“EGFR Y1070 phosphorylation”或“EGFR Ab-1070 antibody”以获取准确信息。
The EGFR (Ab-1070) antibody is a monoclonal antibody specifically designed to target the epidermal growth factor receptor (EGFR), a transmembrane tyrosine kinase receptor involved in regulating cell proliferation, survival, and differentiation. EGFR is overexpressed or mutated in various cancers, including non-small cell lung cancer (NSCLC), colorectal cancer, and glioblastoma, making it a critical therapeutic and diagnostic target. The Ab-1070 clone recognizes an epitope within the extracellular domain of human EGFR, enabling its use in detecting both wild-type and certain mutant forms of the receptor in research applications such as Western blotting, immunohistochemistry (IHC), and flow cytometry.
Developed to support both basic and translational research, this antibody aids in studying EGFR signaling pathways, ligand-receptor interactions, and downstream effectors like MAPK and PI3K/AKT. Its specificity and reliability have made it a valuable tool for evaluating EGFR expression levels in tumor samples, which correlates with prognosis and therapeutic response. Additionally, EGFR (Ab-1070) is employed in preclinical studies to assess the efficacy of EGFR-targeted therapies, such as tyrosine kinase inhibitors (TKIs) and antibody-drug conjugates (ADCs). While not directly used as a therapeutic agent itself, its role in elucidating EGFR biology and resistance mechanisms contributes to the development of personalized cancer treatments. Validation across multiple platforms ensures its utility in diverse experimental models, underscoring its importance in oncology research.
×
